List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 465 studies with search of: Open Studies | "Multiple Myeloma"
Include studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
Conditions: Multiple Myeloma;   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: plerixafor;   Drug: filgrastim
2 Not yet recruiting Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
Conditions: Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: cyclophosphamide;   Drug: thalidomide;   Drug: dexamethasone
3 Not yet recruiting Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Multiple Myeloma;   Refractory Multiple Myeloma
Interventions: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Drug: bortezomib;   Drug: melphalan;   Drug: anti-thymocyte globulin;   Drug: sirolimus;   Drug: tacrolimus;   Radiation: total-body irradiation
4 Recruiting Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
Conditions: Multiple Myeloma and Plasma Cell Neoplasm;   Renal Failure
Interventions: Drug: chemotherapy;   Drug: dexamethasone;   Procedure: plasmapheresis
5 Recruiting High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: cyclophosphamide;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation
6 Recruiting Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone;   Drug: temsirolimus;   Genetic: mutation analysis;   Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
7 Recruiting Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Persistent Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: lenalidomide;   Drug: vorinostat;   Other: fluorescence activated cell sorting;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
8 Recruiting Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: obatoclax mesylate
9 Recruiting Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Conditions: Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Intervention: Drug: alvocidib
10 Recruiting Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone;   Drug: lenalidomide;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: staining method;   Procedure: bone marrow aspiration
11 Recruiting Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: prednisone;   Drug: thalidomide;   Other: clinical observation
12 Recruiting Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: recombinant interferon alfa;   Biological: recombinant interleukin-6
13 Recruiting Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: melphalan;   Drug: pegylated liposomal doxorubicin hydrochloride
14 Recruiting Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: vorinostat
15 Recruiting Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: melphalan;   Drug: panobinostat
16 Recruiting Bevacizumab, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Stage II or Stage III Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: bevacizumab;   Drug: dexamethasone;   Drug: lenalidomide;   Genetic: fluorescence in situ hybridization;   Genetic: polymorphism analysis;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
17 Recruiting Liposomal Doxorubicin, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: pegylated liposomal doxorubicin hydrochloride
18 Recruiting Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
Conditions: Drug/Agent Toxicity by Tissue/Organ;   Mucositis;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: palifermin;   Drug: melphalan;   Other: questionnaire administration;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: quality-of-life assessment
19 Recruiting Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
Conditions: Drug/Agent Toxicity by Tissue/Organ;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: anti-thymocyte globulin;   Drug: sirolimus;   Other: pharmacological study
20 Recruiting Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
Conditions: Graft Versus Host Disease;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Genetic: fluorescence in situ hybridization;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: syngeneic bone marrow transplantation;   Radiation: total-body irradiation

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services